Downing Development Capital
Downing’s award-winning team focuses on partnering with exceptional management teams to help realise their growth ambitions. Healthcare is a specialist subsector of ours and we look to partner with high-quality businesses within the Elderly Care, Specialist Adult Care and Special Educational Needs spaces
Over £200m
invested since 2012
Track record
32 investments completed and 13 exited since inception
Specialist team
11 investment professionals
Subsectors
Elderly Care, Adult Care, Special Educational Needs
Investment approach
With a successful 10-year track record, Downing’s Development Capital team targets strong returns with strong downside protection.
Our time-tested approach can achieve attractive risk-adjusted returns and is based on several criteria:
Strong management
- Proven individuals with extensive experience in their niches
- Focus on quality and excellent service delivery
- Aligned on sustainable business growth
- Experience in putting teams together and creating platforms
Attractive market fundamentals
- Strong underlying demand drivers
- Fragmented market(s)
- Positive supply/demand dynamics and local market demographics
- High barriers to entry
- Positive social impacts
Flexible structure
- Highly attractive risk-adjusted returns
- Team has experience across debt, equity and hybrid deal structures
- Buyouts, buyins and growth capital
- Management contribution ensuring alignment of interests
High-quality assets
- Primary focus on operating businesses
- High-quality properties and assets
- Freehold assets
- Businesses that trade as market leaders
Case studies
Meet the team
Development Capital news & views
Contact us
If you are an institutional investor or adviser, please email Oren Laufer oren.laufer@downing.co.uk or call us on 020 3954 9905
Our investment strategies
Welcome to Downing LLP
Please tell us who you are...
None of the information provided is investment or tax advice.
You should always read the associated risks before deciding whether to invest. These can be found on the product pages as well as in our risks overview.
Please confirm you have read the information above.